Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial
Authors:
- 29 January 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 30 (2) , 1-8
Abstract
Noncardiac chest pain is associated with poor quality of life and high care expenditure. The majority of noncardiac chest pain is either gastresophageal reflux disease related or due to esophageal motility disorders, and the rest are considered functional chest pain (FCP) due to central and peripheral hypersensitivity. Current treatment of FCP improves 40-50% of patients. Cannabinoid receptors 1 (CB1) and 2 (CB2) modulate release of neurotransmitters; CB1 is located in the esophageal epithelium and reduces excitatory enteric transmission and potentially could reduce esophageal hypersensitivity. We performed a prospective study to evaluate its effects on pain threshold, frequency, and intensity in FCP. Subjects with FCP received dronabinol (5 mg, twice daily; n = 7; average age, 44 years; mean body mass index, 26.7) or placebo (n = 6; average age, 42 years; mean body mass index, 25.9) for 28 days (4 weeks). Chest pain, general health, and anxiety/depression questionnaires were assessed at baseline and at 4 weeks. Subjects underwent an esophageal balloon distention test prior to treatment and on last day of the study. Dronabinol increased pain thresholds significantly (3.0 vs. 1.0; P = 0.03) and reduced pain intensity and odynophagia compared to placebo (0.18 vs. 0.01 and 0.12 vs. 0.01, respectively, P = 0.04). Depression and anxiety scores did not differ between the groups at baseline or after treatment. No significant adverse effects were observed. In this novel study, dronabinol increased pain threshold and reduced frequency and intensity of pain in FCP. Further, large scale studies are needed to substantiate these findings.Keywords
Funding Information
- ACG clinical research grant award
This publication has 44 references indexed in Scilit:
- Heterogeneity of mucosal mast cell infiltration in subgroups of patients with esophageal chest painNeurogastroenterology & Motility, 2014
- Societal costs of non-cardiac chest pain compared with ischemic heart disease - a longitudinal studyBMC Health Services Research, 2013
- Theophylline Improves Esophageal Chest Pain?A Randomized, Placebo-Controlled StudyAmerican Journal of Gastroenterology, 2007
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- Non‐cardiac chest pain: an updateNeurogastroenterology & Motility, 2006
- Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double‐blind, placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2006
- Non‐cardiac chest pain: predictors of health care seeking, the types of health care professional consulted, work absenteeism and interruption of daily activitiesAlimentary Pharmacology & Therapeutics, 2004
- Blockade of calcium entry in smooth muscle cells by the antidepressant imipramineBiochemical Pharmacology, 2004
- Antidepressant Treatment of Patients with Diffuse Esophageal SpasmJournal of Clinical Gastroenterology, 1999
- Low-Dose Trazodone for Symptomatic Patients With Esophageal Contraction AbnormalitiesGastroenterology, 1987